Literature DB >> 11391698

Neuronal and glial beta-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology.

S Rossner1, J Apelt, R Schliebs, J R Perez-Polo, V Bigl.   

Abstract

We measured tissue distribution and expression pattern of the beta-site amyloid precursor protein (APP)-cleaving enzyme (BACE) in the brains of transgenic Tg2576 mice that show amyloid pathology. BACE protein was expressed at high levels in brain; at lower levels in heart and liver; and at very low levels in pancreas, kidney, and thymus and was almost absent in spleen and lung when assayed by Western blot analysis. We observed strictly neuronal expression of BACE protein in the brains of nontransgenic control mice, with the most robust immunocytochemical labeling present in the cerebral cortex, hippocampal formation, thalamus, and cholinergic basal forebrain nuclei. BACE protein levels did not differ significantly between control and transgenic mice or as a result of aging. However, in the aged, 17-month-old Tg2576 mice there was robust amyloid plaque formation, and BACE protein was also present in reactive astrocytes present near amyloid plaques, as shown by double immunofluorescent labeling and confocal laser scanning microscopy. The lack of astrocytic BACE immunoreactivity in young transgenic Tg2576 mice suggests that it is not the APP overexpression but rather the amyloid plaque formation that stimulates astrocytic BACE expression in Tg2576 mice. Our data also suggest that the neuronal overexpression of APP does not induce the overexpression of its metabolizing enzyme in neurons. Alternatively, the age-dependent accumulation of amyloid plaques in the Tg2576 mice does not require increased neuronal expression of BACE. Our data support the hypothesis that neurons are the primary source of beta-amyloid peptides in brain and that astrocytic beta-amyloid generation may contribute to amyloid plaque formation at later stages or under conditions when astrocytes are activated. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391698     DOI: 10.1002/jnr.1095

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  31 in total

1.  Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brains.

Authors:  A Kodam; M Maulik; K Peake; A Amritraj; K S Vetrivel; G Thinakaran; J E Vance; S Kar
Journal:  Glia       Date:  2010-08-15       Impact factor: 7.452

2.  miR-186 is decreased in aged brain and suppresses BACE1 expression.

Authors:  Jaekwang Kim; Hyejin Yoon; Dah-Eun Chung; Jennifer L Brown; Krystal C Belmonte; Jungsu Kim
Journal:  J Neurochem       Date:  2016-03-30       Impact factor: 5.372

3.  Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter.

Authors:  Bryan Maloney; Yuan-Wen Ge; Nigel H Greig; Debomoy K Lahiri
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

4.  Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice.

Authors:  Masaru Yamamoto; Tomomi Kiyota; Masahide Horiba; James L Buescher; Shannon M Walsh; Howard E Gendelman; Tsuneya Ikezu
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

5.  Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development.

Authors:  Xue-Mei Zhang; Yan Cai; Kun Xiong; Huaibin Cai; Xue-Gang Luo; Jia-Chun Feng; Richard W Clough; Robert G Struble; Peter R Patrylo; Xiao-Xin Yan
Journal:  Eur J Neurosci       Date:  2009-12-10       Impact factor: 3.386

Review 6.  The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy.

Authors:  Christopher R Sibley; Matthew J A Wood
Journal:  J Mol Med (Berl)       Date:  2011-07-13       Impact factor: 4.599

7.  BACE1 and presenilin/γ-secretase regulate proteolytic processing of KCNE1 and 2, auxiliary subunits of voltage-gated potassium channels.

Authors:  Carolyn C Sachse; Young Hye Kim; Marianne Agsten; Tobias Huth; Christian Alzheimer; Dora M Kovacs; Doo Yeon Kim
Journal:  FASEB J       Date:  2013-03-15       Impact factor: 5.191

8.  Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Authors:  Daniel Paris; Nowell J Ganey; Vincent Laporte; Nikunj S Patel; David Beaulieu-Abdelahad; Corbin Bachmeier; Amelia March; Ghania Ait-Ghezala; Michael J Mullan
Journal:  J Neuroinflammation       Date:  2010-03-08       Impact factor: 8.322

9.  Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease.

Authors:  Jennifer L Furman; Diana M Sama; John C Gant; Tina L Beckett; M Paul Murphy; Adam D Bachstetter; Linda J Van Eldik; Christopher M Norris
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

10.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.